Zacks Investment Research downgraded shares of Quotient (NASDAQ:QTNT) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

Several other research firms also recently issued reports on QTNT. Jefferies Financial Group restated a buy rating and issued a $13.50 price target on shares of Quotient in a research note on Wednesday, August 19th. BidaskClub upgraded Quotient from a strong sell rating to a sell rating in a research note on Monday, November 2nd.

QTNT stock opened at $6.03 on Wednesday. The firm has a market capitalization of $609.16 million, a PE ratio of -4.28 and a beta of 2.30. Quotient has a 1-year low of $2.39 and a 1-year high of $10.38. The business’s 50 day simple moving average is $5.25 and its 200 day simple moving average is $6.50.

Quotient (NASDAQ:QTNT) last posted its earnings results on Monday, November 2nd. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. As a group, research analysts predict that Quotient will post -1.27 EPS for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc purchased 2,911,764 shares of Quotient stock in a transaction that occurred on Tuesday, September 15th. The stock was acquired at an average cost of $4.25 per share, for a total transaction of $12,374,997.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC lifted its position in shares of Quotient by 21.9% during the 3rd quarter. Perceptive Advisors LLC now owns 16,200,818 shares of the company’s stock valued at $83,272,000 after acquiring an additional 2,911,764 shares during the period. Polar Capital LLP lifted its position in shares of Quotient by 21.9% during the 3rd quarter. Polar Capital LLP now owns 9,251,653 shares of the company’s stock valued at $47,553,000 after acquiring an additional 1,660,588 shares during the period. BlackRock Inc. lifted its position in shares of Quotient by 21.2% during the 3rd quarter. BlackRock Inc. now owns 3,851,892 shares of the company’s stock valued at $19,799,000 after acquiring an additional 672,475 shares during the period. Hudson Bay Capital Management LP lifted its position in shares of Quotient by 28.7% during the 2nd quarter. Hudson Bay Capital Management LP now owns 1,525,000 shares of the company’s stock valued at $11,285,000 after acquiring an additional 340,000 shares during the period. Finally, Allianz Asset Management GmbH lifted its position in shares of Quotient by 21.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,242,103 shares of the company’s stock valued at $6,384,000 after acquiring an additional 215,936 shares during the period. Hedge funds and other institutional investors own 77.64% of the company’s stock.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening.

Featured Story: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Quotient (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.